EcoDrugPlus

Matrix Metallopeptidase 13

Ensembl ID : ENSMPUG00000006840
Gene Symbol: MMP13
4 Cross references
200 Possible Orthologues:

Matrix Metallopeptidase 14

Ensembl ID : ENSMPUG00000007212
Gene Symbol: MMP14
2 Cross references
269 Possible Orthologues:

Matrix Metallopeptidase 2

Ensembl ID : ENSMPUG00000003387
Gene Symbol: MMP2
2 Cross references
209 Possible Orthologues:

Matrix Metallopeptidase 7

Ensembl ID : ENSMPUG00000007166
Gene Symbol: MMP7
2 Cross references
163 Possible Orthologues:

Matrix Metallopeptidase 8

Ensembl ID : ENSMPUG00000006884
Gene Symbol: MMP8
2 Cross references
111 Possible Orthologues:

Matrix Metallopeptidase 9

Ensembl ID : ENSMPUG00000017609
Gene Symbol: MMP9
4 Cross references
214 Possible Orthologues:

Mechanistic Target Of Rapamycin Kinase

Ensembl ID : ENSMPUG00000016429
Gene Symbol: MTOR
2 Cross references
214 Possible Orthologues:

Melanocortin 3 Receptor

Ensembl ID : ENSMPUG00000020172
Gene Symbol: MC3R
2 Cross references
138 Possible Orthologues:

Melanocortin 4 Receptor

Ensembl ID : ENSMPUG00000019609
Gene Symbol: MC4R
2 Cross references
121 Possible Orthologues:

Melatonin Receptor 1a

Ensembl ID : ENSMPUG00000010329
Gene Symbol: MTNR1A
4 Cross references
205 Possible Orthologues:

Membrane Metalloendopeptidase

Ensembl ID : ENSMPUG00000002746
Gene Symbol: MME
2 Cross references
231 Possible Orthologues:

Methionyl Aminopeptidase 2

Ensembl ID : ENSMPUG00000007214
Gene Symbol: METAP2
2 Cross references
212 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).